Scholarlink

Background <p>Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for major depressive disorder (MDD) with a low incidence of adverse effects. However, bradycardia is not commonly recognized as an adverse effect of rTMS. In this case report, we present the first documented instance of a patient with MDD and premature ventricular contractions (PVCs) who developed severe bradycardia following rTMS treatment.</p> Case presentation <p>We report the case of a 46-year-old Chinese woman with a 7-year history of MDD and a 6-year history of PVCs. She had been taking paroxetine, tandospirone citrate, and metoprolol long-term without experiencing bradycardia. After initiating rTMS treatment, she developed severe bradycardia. Even after discontinuing metoprolol, the severe bradycardia persisted for several days. Notably, the severe bradycardia disappeared one day after pausing rTMS therapy. When rTMS was resumed, the bradycardia reoccurred and subsequently resolved again upon pausing the rTMS treatment.</p> Conclusion <p>The influence of rTMS on heart rate (HR) is likely mediated through the autonomic nervous system (ANS). Currently, severe arrhythmias are not widely recognized as adverse effects of rTMS. While the exact mechanisms by which rTMS affects the cardiovascular system remain unclear, this case underscores the necessity for caution when using rTMS to treat psychiatric patients with arrhythmias.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Severe bradycardia triggered by repetitive transcranial magnetic stimulation in a patient with major depressive disorder and premature ventricular contractions: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月30日

查看全文
  • Shuping Fang,
  • Bowen Song,
  • Xin Yang,
  • Ling Ma,
  • Zhe Li

摘要

Background

Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for major depressive disorder (MDD) with a low incidence of adverse effects. However, bradycardia is not commonly recognized as an adverse effect of rTMS. In this case report, we present the first documented instance of a patient with MDD and premature ventricular contractions (PVCs) who developed severe bradycardia following rTMS treatment.

Case presentation

We report the case of a 46-year-old Chinese woman with a 7-year history of MDD and a 6-year history of PVCs. She had been taking paroxetine, tandospirone citrate, and metoprolol long-term without experiencing bradycardia. After initiating rTMS treatment, she developed severe bradycardia. Even after discontinuing metoprolol, the severe bradycardia persisted for several days. Notably, the severe bradycardia disappeared one day after pausing rTMS therapy. When rTMS was resumed, the bradycardia reoccurred and subsequently resolved again upon pausing the rTMS treatment.

Conclusion

The influence of rTMS on heart rate (HR) is likely mediated through the autonomic nervous system (ANS). Currently, severe arrhythmias are not widely recognized as adverse effects of rTMS. While the exact mechanisms by which rTMS affects the cardiovascular system remain unclear, this case underscores the necessity for caution when using rTMS to treat psychiatric patients with arrhythmias.